Loading
A phase 2 trial of Carboplatin, Doxorubicin, Pegylated liposomal doxorubicin, Gemcitabine and Mirvetuximab soravtansine in ovarian cancer, run by AGO Research GmbH, active and no longer recruiting.
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT04274426 by AGO Research GmbH, with 136 participants enrolled, started 2021-10-13 and due to reach its primary completion in 2025-12-03. Interventions recorded: Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel and Mirvetuximab Soravtansine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pegylated liposomal doxorubicin, Doxorubicin, Gemcitabine, Ovarian cancer and the tag pipeline.
Shares AGO Study Group, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Gemcitabine, Ovarian cancer and the tag pipeline.
Shares Gemcitabine, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gemcitabine, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Doxorubicin, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gemcitabine, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/